The acquisition, subject to regulatory approvals and customary closing formalities, will be completed for a total consideration of JPY 21.5 billion, approximately ₹1,300 crore. The company said the transaction will be funded through a mix of debt and equity.
MBJ is engaged in research, development and manufacturing of APIs, intermediates and contract development and manufacturing (CDMO) services. The company has capabilities in microbial fermentation and biotechnology-based manufacturing and operates across oncology APIs, plasmid DNA manufacturing, ADC conjugation and enzyme-based bioconversion platforms.
Also Read: Gujarat Themis shares jump 10% on €158 million Sanofi anti-TB portfolio deal
GTBL said the acquisition is part of its strategy to expand from a fermentation-led intermediates business into a technology-driven CDMO platform with capabilities across precision fermentation, biotechnology and next-generation drug manufacturing.
The transaction is subject to approval under Japan’s Foreign Exchange and Foreign Trade Act (FEFTA) and other regulatory approvals. The company expects the acquisition to close in Q2 FY27, subject to satisfaction of customary closing conditions.
MBJ reported estimated revenue of JPY 9.5 billion, approximately ₹570 crore, for FY26. The company’s revenue from operations over the last three years stood at approximately ₹470 crore in FY23, ₹580 crore in FY24 and ₹560 crore in FY25.
Also Read: Aurobindo Pharma’s Rajasthan unit gets 7 observations from US FDA
GTBL said the acquisition is not a related party transaction and that the promoter or promoter group has no interest in the entity being acquired.
Shares of Gujarat Themis Biosyn Ltd ended at ₹364.50, up by ₹7.40, or 2.07%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
